Introduction
Human cytomegalovirus (CMV) disease is a major cause of morbidity and mortality during the period of immune suppression after bone marrow transplantation (BMT).
CMV reactivation is commonly associated with allogeneic stem cell transplantation (alloSCT) and can occur following autologous SCT (autoSCT) procedures, albeit at a lower incidence. 1 Furthermore, the use of novel immunosuppressive agents, such as alemtuzumab (Campath) and fludarabine, is associated with an increased frequency of this disease. 2 In alloSCT, preemptive therapy based on CMV detection in blood has largely replaced prophylactic administration of ganciclovir to all high-risk patients. [3] [4] [5] [6] Non-directed use of ganciclovir causes myelosuppression, resulting in an increased incidence of fungal and bacterial infections and delays in immune reconstitution. 7 Approximately 60-70% of patients at high risk of CMV will experience reactivation after alloSCT, and without ganciclovir prophylaxis or preemptive therapy, 10-26% of these will develop end-organ disease, with reported associated mortality of 50%. 3, 4, 7 The CMV real-time polymerase chain reaction (RT-PCR) assay has increased sensitivity compared with antigenemia testing. The assay is of particular value in neutropenic patients, with detection of CMV reported up to 8 days before a positive antigen test. 8, 9 Preemptive therapy based on CMV RT-PCR therefore allows treatment to be initiated earlier, and so should afford reduced treatment duration and risk of CMV disease compared with antigenemia testing. 10 The current cohort reports a single institution experience of RT-PCR for the detection of CMV DNA, and the institution of preemptive therapy for CMV disease based on these results in more than 500 patients undergoing SCT.
Patients and methods
A total of 577 consecutive patients undergoing autologous and allogeneic SCT between January 1998 and April 2003 were evaluated retrospectively. Patients undergoing two procedures, that is autologous and allogeneic SCT, were evaluated on the basis of their preceding transplant procedures. Patient and disease characteristics of patients undergoing autologous and allogeneic SCT procedures are shown in Tables 1 and 2 , respectively. All patients gave informed consent for the SCT procedure and local ethics committee approval was available for specific SCT protocols.
Conditioning regimens
The conditioning regimen for autoSCT was commonly BEAM, 11 CBV 12 or melphalan 200 mg/m 2 7total body irradiation (TBI) (in all patients with myeloma and normal renal function) ( Table 1) .
The most common conditioning regimens for alloSCT were cyclophosphamide 60 mg/kg with mesna/TBI 1200 cGy and cyclophosphamide 60 mg/kg with mesna/ TBI 1200 cGy/Campath 10 mg days À4 to 0 (both myeloablative), and fludarabine 30 mg/m 2 day À7 to À3/melphalan 140 mg/m 2 day À2/Campath 10 mg/bd day À8 to À4 (nonmyeloablative) ( Table 2) .
Graft versus host disease prophylaxis
Patients undergoing a myeloablative sibling matched SCT or matched unrelated donor (MUD) SCT received graft versus host disease (GVHD) prophylaxis comprising cyclosporin (5 mg/kg) and methotrexate (day 1 at 15 mg/ m 2 , and days 3, 6 and 11 at 10 mg/m 2 ). Cyclosporin dose was adjusted on renal function and daily cyclosporin levels.
Those patients receiving nonmyeloablative conditioning received only cyclosporin at a dose of 5 mg/kg as GVHD prophylaxis. GVHD was assessed by the Seattle classification. 13 Anti-infection prophylaxis Antiviral prophylaxis consisted of acyclovir 200 mg orally four times daily switching to 250 mg twice daily intravenous (i.v.) if unable to take enteral medication. All patients received pneumocytis carinii pneumonia prophylaxis with oral or i.v. cotrimoxazole 960 mg twice daily, twice weekly from admission. Nebulized pentamidine (300 mg every 3 weeks preceded by salbutamol nebulizer) was administered in cases of allergy or intolerance, or in cases of persisting cytopenia. Antifungal prophylaxis comprised fluconazole 100 mg once daily for all patients undergoing SCT, itraconazole 200 mg twice daily for patients undergoing sibling allogeneic SCT and voriconazole twice daily for patients undergoing MUD SCT and as secondary prophylaxis. Antiviral and antifungal prophylaxis was continued for a minimum of 3 months and patients post-MUD SCT were discharged on itraconazole.
Ciprofloxacin 500 mg was administered twice daily during periods of neutropenia in patients undergoing MUD SCT, with transfer to twice daily oral penicillin V 250 mg on engraftment.
Transfusion policy CMV serostatus was determined before transplantation by complement fixation testing of IgM and IgG CMV. CMV serostatus is shown in Tables 1 and 2. All patients with CMV negative serostatus received irradiated CMV-negative products and CMV-positive patients received irradiated, CMV-unscreened blood products.
CMV surveillance protocol Samples were taken for CMV analysis once weekly for the first 21 days post-autoSCT or for duration of hospitalization or if symptomatic. Surveillance for alloSCT patients comprised weekly evaluation for periods extending up to 120 days, or longer if patients experienced symptoms compatible with CMV disease.
Detection of CMV CMV RT-PCR was performed on EDTA-anticoagulated whole blood using Taqman quantitative CMV PCR. Briefly, DNA was extracted from 1 ml volume of blood using the Nucleon blood extraction kit BCC1 (Nucleon Biosciences, Glasgow, UK) and amplified using a previously described Taqman quantitative CMV PCR assay. 9 The limit of detection for this assay was defined as 500 CMV DNA genome copies/ml. CMV antigenemia was estimated using the immunoassay described previously. 9 CMV treatment protocol Antiviral therapy was initiated in patients with two consecutive positive CMV PCR results and viral DNA copy numbers o1000 (log 3) or a single positive CMV PCR result and viral DNA copy number X1000 (log values 4log 3). Initial treatment comprised i.v. ganciclovir 5 mg/ kg twice daily until demonstration of two consecutive negative CMV PCR results and resolution of clinical symptoms. Patients with ganciclovir-associated myelosuppression (neutrophil count o1.0 Â 10 9 /l) received granulocyte colony-stimulating factor (G-CSF; lenograstim 263 mg or filgrastim 300 mg).
CMV treatment was changed to foscarnet 90 mg/kg i.v. twice daily if the neutrophil count remained o1.0 Â 10 9 /l. If CMV PCR positivity persisted and/or DNA copy numbers increased after 14 days, or the patient deteriorated clinically, combination therapy comprising once daily ganciclovir (5 mg/kg) and foscarnet (45 mg/kg) was commenced.
For the first episode of reactivation, patients underwent CMV surveillance by PCR twice weekly to determine duration of CMV therapy. For patients with recurrent activation, a maintenance regimen comprising ganciclovir (5 mg/kg) administered once daily, three times a week was continued for 100 days.
CMV disease
Broncho-alveolar lavage (BAL) was performed if a patient had symptoms or radiological evidence of interstitial lung disease by X-ray or high resolution CT scanning. All patients with gastrointestinal symptoms underwent endoscopy with biopsy.
CMV pneumonia was diagnosed on the basis of signs/or symptoms of pulmonary disease (dyspnoea, interstitial infiltrates on chest radiograph), with the detection of a positive CMV culture of bronchial lavage or lung tissue samples. Detection of CMV should be performed by virus isolation, histopathological testing and immunohistochemistry. A diagnosis of CMV enteritis was based on clinical and endoscopic signs of enteritis plus histological demonstration of CMV inclusions, positive in situ hybridization assays, or positive culture for CMV from tissue samples obtained at biopsy. All positive histological samples were re-reviewed to confirm a diagnosis of CMV. All patients with retinitis had lesions typical of CMV retinitis confirmed by opthalmologist.
CMV-related mortality was defined as death occurring within 6 weeks of the diagnosis of CMV disease.
Statistical analysis
The primary end point of this study was to assess the safety of preemptive CMV therapy directed by quantitative RT-PCR and the relevance of this approach to the early detection of end-organ disease. All risk factors were assessed in relation to CMV reactivation, including risk status, age, sex, GVHD, source of stem cells, transplant conditioning and underlying disease. The effects of the risk factors on the development of CMV reactivation were assessed by univariate and multivariate Cox regression with censoring at death, subsequent transplantation, or end of follow-up. All charts are based on Kaplan-Meier plots for reactivation rates.
Results
A total of 408 patients underwent autoSCT; 368 patients had haematological malignancy and 40 patients had solid tumours. The median age of patients who underwent autoSCT was 51 years (range 16-70 years), with a slight predominance of males. AlloSCT was performed in 172 patients; 86 human leukocyte antigen (HLA)-matched sibling donors, 85 HLA-MUD and one syngeneic donor. The median age of patients who underwent alloSCT was 39 years (range 16-66 years). Leukaemia was the most common underlying disease in patients receiving alloSCT. HLA matching was undertaken using DNA typing and all patients were matched for A, B and DR loci.
AutoSCT patients -reactivation of CMV A total of 405 patients underwent autoSCT and of these 208 (51%) were seropositive for CMV, indicating previous exposure to the virus. At median follow-up of 45 months post-transplant, six patients (1.5%) experienced CMV reactivation as evidenced by detection of increased CMV viral copy number. Median time to reactivation was 26.5 days post transplant (range 12-57) and median viral copy numbers was 15488 copies/ml (range 500-367 846). Of the six patients with CMV reactivation, four had myeloma, one had relapsed non-Hodgkin's lymphoma (NHL) and one had relapsed acute myeloid leukaemia (AML). Of the four patients with myeloma and CMV reactivation, two required treatment for associated symptoms (pyrexia and diarrhoea) but responded well. These patients subsequently underwent reduced intensity sibling alloSCT and experienced CMV reactivation requiring treatment and long-term maintenance therapy. Two patients with CMV reactivation and myeloma demonstrated transient positivity and remained completely asymptomatic, and did not therefore require treatment. The two nonmyeloma patients with CMV reactivation had early and florid relapse of ALL or NHL and in these patients. The patient with NHL died of chemo-resistant disease 2 weeks later and the other patient had only transient positivity and underwent ALL relapse therapy, but died 12 months later from ALL.
AlloSCT patients -reactivation of CMV A total of 172 alloSCT procedures were undertaken during the study period. At a median follow-up of 30 months following transplant, 51 (30%) experienced CMV reactivation. Reactivation was observed at a median of 29.5 days (range 12-282) post-transplant with a median viral copy number of 8967 copies/ml (range 500-9 538 300). Three out of four patients reactivating by day 15 were DÀR þ graft patients, the other D þ R . In three patients, reactivation was observed after 100 days and occurred in association with disease relapse. CMV reactivation was observed in one out of 87 patients (1.1%) at low risk for CMV reactivation (e.g. negative donor and recipient) ( Table 3 ). This patient was heavily immunosuppressed after receiving antithymocyte globulin (ATG) reconditioning before second transplant. Of the other patients receiving ATG/ALG for transplantation, the majority of patients were low risk but only 2/11 patients reactivated.
Risk factors for CMV reactivation post-allogeneic transplant (Table 4) Risk factors analysed as part of our group were age, sex, patient-donor risk status, MUD versus sibling donor, transplant conditioning, GVHD and source of transplantation cells. Chronic GVHD was not evaluated as a risk factor, as only three patients developed CMV reactivation after 100 days; in these patients chronic GVHD was not observed and reactivation was observed in associated with disease relapse.
The risk factors for developing CMV reactivation on multivariate and univariate analyses are shown in Table 4 . Multivariate analysis confirmed CMV seropositivity before SCT of donor and/or graft recipient is the strongest predicting factor for CMV reactivation. (Figure 1 ; Po0.001). Myeloma also represented a significant risk factor for CMV reactivation (P ¼ 0.04; Figure 2 ). Although univariate analyses demonstrated that age, source of stem cells (Figure 3 ), GVHD and transplant conditioning ( Figure 4 ) were significant risk factors, multivariate analyses failed to confirm that these parameters represented independent risk factors for CMV reactivation.
CMV disease (Table 5) Of the 51 patients with CMV reactivation, eight developed CMV end-organ disease, including retinitis (n ¼ 3), colitis (n ¼ 3), pneumonitis (n ¼ 1) and skin infiltration (n ¼ 1), at a median of 186 days post-transplant (range 25-800) ( Table 5) . Notably CMV disease was observed before 100 days post-transplant in only one patient. All patients with CMV disease were high risk and reactivated early, as Table 3 CMV reactivation risk status (according to donor status) and outcome
Risk status
No. of patients CMV reactivation, n (%) of patients at risk demonstrated by CMV PCR positivity at a median of 26 days post-transplant (range 15-36). Four of the patients with detectable end-organ disease (two patients with retinitis, one patient with colitis and one patient with pneumonia) had no detectable virus in peripheral blood at time of CMV disease onset, thereby demonstrating a lack of correlation between CMV PCR positivity and active end-organ disease. Of these patients, two remained PCRnegative until death or resolution of CMV disease and one developed CMV PCR positivity 35 days after disease onset (the patient with CMV colitis). The remaining patients were not rechecked owing to relapsed disease. Three patients died of CMV-related causes (one pneumonia, two colitis) during the 5-year period.
Discussion
This study in a large cohort of patients confirms the fact that autoSCT patients who are seropositive may be at, albeit low, risk from reactivation. Rates of 0-22% have been previously reported in this setting, 14 with the higher reactivation rates reported in patients who had received CD34 þ -selected, and therefore largely T-cell depleted, peripheral blood stem cell transplant (PBSCT). In a case series of 795 patients who underwent autoSCT, CMV pneumonia was observed in 2% of patients and was associated with seropositivity before transplant. 15 Although prompt treatment generally yielded a favourable response, mortality was significant at 31%. More intensive regimens, including fludarabine and tandem transplants, have been associated with reactivation of CMV. 16, 17 In the current series of patients who underwent preemptive monitoring, CMV disease was not observed in association with autoSCT. The absence of CMV disease in this series is due either to a less severe natural history of CMV disease in this setting or to surveillance assisting in early detection and treatment. Notably, four of the six patients who experienced reactivation after autoSCT had multiple myeloma, lending particular support to suspicion in a symptomatic patient. We would advocate early CMV testing in a symptomatic patient especially in the context of myeloma disease.
In allogeneic transplantation we have noted a high incidence of reactivation, but a low level of end-organ disease. In seven of the eight patients (88%) with end-organ CMV disease, disease onset was observed after 100 days post transplant. The late onset of CMV disease in this setting is in accordance with the recent report of Einsele et al., 7 and confirms later disease onset seen in the era of PCR monitoring and preemptive treatment. Within our cohort of allogeneic transplant patients the organ-specific disease is changing in pattern to rarer sites, rather than the previous more common early CMV-related pneumonia. Additionally, the low rates of CMV disease and CMVrelated mortality (1.7%) in the current series are in accordance with previously published reports. 4, 18 Patients who underwent alloSCT and who remained negative for CMV PCR throughout follow-up did not develop CMV disease, which is in accordance with the recent report by Howden et al. 19 There was a significantly higher reactivation rate in those patients who received CMV naive donor cells than those donors who were CMVseropositive. CMV viraemia was observed in one (1.1%) CMV-negative patients transplanted with CMV-negative stem cells. As a strict transfusion policy was in operation, it is unlikely that this infection was acquired from blood products. It should however be noted that this patient went onto require both reconditioning and graft top-up due to graft failure and reactivated following this. This patient may have experienced primary CMV infection.
Of the 69 patients at high risk of CMV reactivation, 43 (62%) reactivated CMV virus. The majority of these patients reactivated in the early period following transplant (median 31 days, range 12-282 days), although two patients developed CMV positivity after 100 days in the context of relapsed disease.
Multivariate analysis confirmed CMV status of donor and recipient as a risk factor for CMV reactivation. Additionally, myeloma was identified as an independent risk factor for CMV reactivation. The significantly increased reactivation rates within the myeloma patient cohort is likely to be multifactorial, but may well be due to the immune paresis of the underlying disease.
Recently, much emphasis has been placed on the increased likelihood of CMV reactivation following reduced intensity conditioning due to T cell depletion. 18 Reactivation rates of up to 85% and increased CMV disease have been reported in high-risk patients. [20] [21] [22] [23] The reactivation rate of 74% observed in high-risk patients who received reduced intensity conditioning (flu/cam) in the current series is compatible with previous reports. In multivariate analysis, however, an association between low-intensity conditioning and CMV reactivation was not apparent.
Of the eight patients who developed CMV disease, seven had received Campath and three had received reduced intensity conditioning. However, the three patients with CMV disease after reduced intensity alloSCT had a highrisk status for CMV and were older patients, and these factors also may have contributed to the development of CMV disease in these patients. Other risk factors for CMV identified on univariate analysis included GVHD and peripheral blood stem cells (PBSCs) as the source of stem cells. Large multicentre comparisons of PBSCT and BMT have shown no significant evidence of increase in CMV infection following PBSCT, but they have not specifically looked at CMV as a single entity. [24] [25] [26] In more than 500 patients undergoing SCT at a single centre, the introduction of CMV PCR monitoring and preemptive therapy has been associated with a low incidence of CMV end-organ disease and related mortality, with the incidence of CMV pneumonia reduced particularly. Notably, we observed negative CMV PCR in association with active CMV organ disease in half of the eight affected patients, although reactivation had been observed previously in these patients. These findings indicate a poor correlation between CMV PCR and active disease and highlight a need for caution when relying on virus detection at the time of CMV disease. This study therefore supports a preemptive strategy based on sensitive CMV detection to enable early intervention with ganciclovir and consequently reduce the risk of CMV disease.
